© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 6, 443-456,
March 17, 1993
© 1993 Oxford University Press
Photodynamic Therapy in Oncology: Mechanisms and Clinical Use
Correspondence to: Harvey I. Pass, M.D., Thoracic Oncology Section, Surgery Branch, NCI/NIH, Bldg. 10, Rm. 2B07, Bethesda, MD 20892.
In photodynamic therapy (PDT), a sensitizer, light, and oxygen are used to cause photochemically induced cell death. The mechanism of cytotoxicity involves generation of singlet oxygen and other free radicals when the light-excited sensitizer loses or accepts an electron. Although selective retention of sensitizer by malignant tissue is seen in vivo, the mechanisms for this sensitizer targeting remain unclear. The first-generation sensitizers are porphyrin based and vary in lipophilicity and hydrophilicity. Targeting of the vasculature seems to be a prominent feature of the cytotoxic effect of these sensitizers in vivo, with resulting necrosis. Treatment depth varies with the wavelength of light that activates the sensitizer used, and the second-generation sensitizers are activated at longer wavelengths, allowing for a 30% increase in treatment depths. The selectivity of targeting can be increased when the sensitizer is delivered with the use of liposomes or monoclonal antibodies specific for tumor antigens. Studies have demonstrated direct effects of PDT on immune effector cells, specifically those with lineage from macrophages or other monocytes. Clinically, this therapy has been chiefly used for palliation of endobronchial and esophageal obstruction, as well as for treatment of bladder carcinomas, skin malignancies, and brain tumors. The future of PDT rests in defining its use either as an intraoperative adjuvant to marginal surgical procedures or as a primary treatment for superficial malignancies. Phase III trials in esophageal cancer and lung cancer are in progress and will help in evaluation of whether Photofrin II, the most widely used sensitizer, can be added to the oncologic armamentarium, pending approval from the U.S. Food and Drug Administration. [J Natl Cancer Inst 85: 443–456, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. E. Cuenca, R. R. Allison, C. Sibata, and G. H. Downie Breast Cancer With Chest Wall Progression: Treatment With Photodynamic Therapy Ann. Surg. Oncol., March 1, 2004; 11(3): 322 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Subbarayan, U. O. Hafeli, D. K. Feyes, J. Unnithan, S. N. Emancipator, and H. Mukhtar A Simplified Method for Preparation of 99mTc-Annexin V and its Biologic Evaluation for In Vivo Imaging of Apoptosis After Photodynamic Therapy J. Nucl. Med., April 1, 2003; 44(4): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonneau, C. Vever-Bizet, P. Morliere, J.-C. Maziere, and D. Brault Equilibrium and Kinetic Studies of the Interactions of a Porphyrin with Low-Density Lipoproteins Biophys. J., December 1, 2002; 83(6): 3470 - 3481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vantieghem, Y. Xu, Z. Assefa, J. Piette, J. R. Vandenheede, W. Merlevede, P. A. M. de Witte, and P. Agostinis Phosphorylation of Bcl-2 in G2/M Phase-arrested Cells following Photodynamic Therapy with Hypericin Involves a CDK1-mediated Signal and Delays the Onset of Apoptosis J. Biol. Chem., September 27, 2002; 277(40): 37718 - 37731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Itoh, Y. Ninomiya, S. Tajima, and A. Ishibashi Photodynamic Therapy for Acne Vulgaris With Topical 5-Aminolevulinic Acid Arch Dermatol, September 1, 2000; 136(9): 1093 - 1095. [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Kim, B. I. Choi, S. W. Park, W. Lee, J. K. Han, M. C. Han, and H.-J. Weinmann Gadolinium Mesoporphyrin as an MR Imaging Contrast Agent in the Evaluation of Tumors: An Experimental Model of VX2 Carcinoma in Rabbits Am. J. Roentgenol., July 1, 2000; 175(1): 227 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gijsens, L. Missiaen, W. Merlevede, and P. de Witte Epidermal Growth Factor-mediated Targeting of Chlorin e6 Selectively Potentiates Its Photodynamic Activity Cancer Res., April 1, 2000; 60(8): 2197 - 2202. [Abstract] [Full Text]
|
|
|
|
|
|
M. C. Luna, A. Ferrario, S. Wong, A. M. R. Fisher, and C. J. Gomer Photodynamic Therapy-mediated Oxidative Stress as a Molecular Switch for the Temporal Expression of Genes Ligated to the Human Heat Shock Promoter Cancer Res., March 1, 2000; 60(6): 1637 - 1644. [Abstract] [Full Text]
|
|
|
|
|
|
B. W. Engbrecht, C. Menon, A. V. Kachur, S. M. Hahn, and D. L. Fraker Photofrin-mediated Photodynamic Therapy Induces Vascular Occlusion and Apoptosis in a Human Sarcoma Xenograft Model Cancer Res., September 1, 1999; 59(17): 4334 - 4342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Halkiotis, D. Yova, and G. Pantelias In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy Mutagenesis, March 1, 1999; 14(2): 193 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Berg,, P. Kristian Selbo, L. Prasmickaite, T. E. Tjelle, K. Sandvig, J. Moan, G. Gaudernack, O. Fodstad, S. Kjolsrud, H. Anholt, et al. Photochemical Internalization: A Novel Technology for Delivery of Macromolecules into Cytosol Cancer Res., March 1, 1999; 59(6): 1180 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Matroule, G. Bonizzi, P. Morliere, N. Paillous, R. Santus, V. Bours, and J. Piette Pyropheophorbide-a Methyl Ester-mediated Photosensitization Activates Transcription Factor NF-kappa B through the Interleukin-1 Receptor-dependent Signaling Pathway J. Biol. Chem., January 29, 1999; 274(5): 2988 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fritsch, G. Goerz, and T. Ruzicka Photodynamic Therapy in Dermatology Arch Dermatol, February 1, 1998; 134(2): 207 - 214. [Abstract] [Full Text] [PDF]
|
|